Essayer OR - Gratuit

We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM

Bio Spectrum

November 2025

Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram. The event brought together global innovators, researchers, investors, and industry leaders to explore opportunities, collaborations, and advancements across biotechnology, healthcare, digital health, and allied sectors. Organised by the Kerala Life Sciences Industries Park (KLIP) and the Kerala State Industrial Development Corporation (KSIDC), this conclave featured thought-provoking discussions, visionary keynote sessions, and cutting-edge technology showcases.

- Dr Manbeena Chawla

We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM

Kerala Unveils BioEconomy Report 2025

A key highlight of Bio Connect 3.0 was the Government of Kerala releasing the Kerala BioEconomy Report 2025, prepared by the Association of Biotechnology Led Enterprises (ABLE) for Kerala Life Sciences Industries Park, a subsidiary of the Kerala State Industrial Development Corporation.

The report positions Kerala as a national leader in sustainable bio-based growth, mapping a BioEconomy valued at $7.53 billion (Rs 62,000 crore) equivalent to 4.25 per cent of India's national BioEconomy and projecting its expansion to $11-12 billion (Rs 100,000 crore) by 2030. This trajectory is being driven by Ayurveda, biotechnology, marine bioresources, nutraceuticals, and bioindustrial innovation, supported by a rising network of over 300 life science startups and a statewide ecosystem of research institutions and incubators.

The report was released during the inaugural session by P Rajeev, Minister for Law, Industries and Coir of Kerala Government along with A. P. M. Mohammed Hanish, Principal Secretary, Industries, Government of Kerala; Rajesh Kumar Pathak, Secretary, Technology Development Board, Government of India; Timothy Rowe, CEO, (Cambridge Innovation Center) and Co-founder, LabCentral, Boston, US; Vishnuraj, Managing Director, Kerala State Industrial Development Corporation; Dr Praveen KS, CEO, KLIP; Narayanan Suresh, Advisor, ABLE and Dr Balasubramanya S, General Manager, ABLE.

“Kerala’s BioEconomy brings together science, sustainability, and social welfare,” said Pinarayi Vijayan, Chief Minister of Kerala. “By 2030, we aim to make bio-based industries a key pillar of the state’s Gross State Domestic Product (GSDP), creating value through innovation, wellness, and ecological stewardship.”

Cette histoire est tirée de l'édition November 2025 de Bio Spectrum.

Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.

Déjà abonné ? Se connecter

PLUS D'HISTOIRES DE Bio Spectrum

Tout voir

Bio Spectrum

Breaking Ground in Clinical Trials: India's Innovation Imperative

For decades, India has been a global powerhouse in pharmaceutical manufacturing. Yet in clinical trials, the crucial bridge between laboratory discoveries and patient access, the country’s performance has lagged behind its industrial capabilities.

5 mins

November 2025

Bio Spectrum

MOFs for Next-Gen Therapies

Susumu Kitagawa, Richard Robson and Omar M Yaghi have been awarded the Nobel Prize in Chemistry 2025 for the development of a new type of molecular architecture called metal-organic frameworks (MOFs), opening new avenues for applications such as drug delivery, biomedical imaging and personalised medicine.

2 mins

November 2025

Bio Spectrum

We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM

3 mins

November 2025

Bio Spectrum

The AI Job Loss Threat Conundrum

There are assumptions that Artificial Intelligence (AI) will take away pharma and healthcare jobs. But many are of the opinion that AI will help to transform jobs as well as create new ones in the long run. How much pharma and healthcare companies invest in AI and cope with the latest AI innovations will determine who can survive and who will perish. Let's find out.

5 mins

November 2025

Bio Spectrum

Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally

Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.

1 min

November 2025

Bio Spectrum

CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency

India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.

10 mins

November 2025

Bio Spectrum

When Spectra Speak: Letting AI Read the Fine Print of Biologics

Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.

5 mins

November 2025

Bio Spectrum

Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale

Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;

4 mins

November 2025

Bio Spectrum

Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad

Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.

1 min

November 2025

Bio Spectrum

Patient Consent - How is it different under medical ethics and data protection?

In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.

3 mins

November 2025